Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cancer Survivors | 15 | 2024 | 724 | 3.030 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2024 | 2850 | 1.880 |
Why?
|
Neoplasms, Second Primary | 5 | 2021 | 1369 | 1.490 |
Why?
|
Telomere | 4 | 2016 | 516 | 1.370 |
Why?
|
Thyroid Neoplasms | 4 | 2021 | 1897 | 1.200 |
Why?
|
Telomere Shortening | 2 | 2021 | 57 | 1.200 |
Why?
|
Leukemia, Myeloid, Acute | 14 | 2024 | 7070 | 1.050 |
Why?
|
Health Equity | 2 | 2024 | 54 | 1.030 |
Why?
|
Telomerase | 3 | 2020 | 533 | 0.990 |
Why?
|
Child | 45 | 2024 | 30109 | 0.960 |
Why?
|
Telomere-Binding Proteins | 3 | 2020 | 84 | 0.900 |
Why?
|
Mycoses | 2 | 2021 | 386 | 0.880 |
Why?
|
Dyskeratosis Congenita | 2 | 2013 | 26 | 0.880 |
Why?
|
Hodgkin Disease | 4 | 2024 | 1459 | 0.850 |
Why?
|
Neutropenia | 5 | 2023 | 987 | 0.810 |
Why?
|
Telomere Homeostasis | 2 | 2020 | 70 | 0.800 |
Why?
|
Frailty | 2 | 2021 | 129 | 0.780 |
Why?
|
Health Status Disparities | 1 | 2024 | 314 | 0.740 |
Why?
|
Hyperbilirubinemia | 2 | 2022 | 77 | 0.730 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2022 | 200 | 0.720 |
Why?
|
Neoplasms | 12 | 2024 | 15666 | 0.690 |
Why?
|
Decision Support Systems, Clinical | 1 | 2022 | 255 | 0.670 |
Why?
|
Wearable Electronic Devices | 1 | 2021 | 111 | 0.660 |
Why?
|
Megakaryocyte Progenitor Cells | 1 | 2018 | 10 | 0.650 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1927 | 0.620 |
Why?
|
Twins, Monozygotic | 1 | 2018 | 130 | 0.620 |
Why?
|
Long Term Adverse Effects | 1 | 2017 | 23 | 0.600 |
Why?
|
Down Syndrome | 1 | 2020 | 228 | 0.600 |
Why?
|
Internet | 2 | 2022 | 725 | 0.580 |
Why?
|
Bone Diseases, Metabolic | 1 | 2017 | 83 | 0.580 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 608 | 0.570 |
Why?
|
Siblings | 3 | 2019 | 288 | 0.570 |
Why?
|
Genetic Predisposition to Disease | 6 | 2024 | 5381 | 0.560 |
Why?
|
Adolescent | 27 | 2024 | 32261 | 0.560 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 204 | 0.560 |
Why?
|
Infertility | 1 | 2017 | 119 | 0.530 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2018 | 462 | 0.510 |
Why?
|
Radiotherapy | 3 | 2021 | 1852 | 0.500 |
Why?
|
Genetic Variation | 2 | 2020 | 2041 | 0.500 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2020 | 4316 | 0.490 |
Why?
|
Cognition Disorders | 1 | 2020 | 787 | 0.480 |
Why?
|
Gene Rearrangement | 1 | 2018 | 797 | 0.480 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2022 | 6783 | 0.470 |
Why?
|
Humans | 61 | 2024 | 269838 | 0.460 |
Why?
|
Minisatellite Repeats | 1 | 2013 | 50 | 0.440 |
Why?
|
Child, Preschool | 16 | 2024 | 16743 | 0.410 |
Why?
|
Survivors | 5 | 2024 | 1028 | 0.410 |
Why?
|
Neurotoxicity Syndromes | 2 | 2024 | 119 | 0.410 |
Why?
|
Neutrophils | 1 | 2016 | 844 | 0.410 |
Why?
|
Leukemia, Myeloid | 1 | 2016 | 965 | 0.390 |
Why?
|
Steroids | 1 | 2013 | 355 | 0.390 |
Why?
|
Anemia, Aplastic | 1 | 2013 | 230 | 0.390 |
Why?
|
Fetal Growth Retardation | 1 | 2013 | 205 | 0.390 |
Why?
|
Health Planning Guidelines | 1 | 2011 | 58 | 0.370 |
Why?
|
Antifungal Agents | 2 | 2021 | 853 | 0.370 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2589 | 0.360 |
Why?
|
Obesity | 3 | 2018 | 2986 | 0.360 |
Why?
|
Microcephaly | 1 | 2013 | 328 | 0.350 |
Why?
|
Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.350 |
Why?
|
Risk Factors | 13 | 2024 | 18032 | 0.340 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 16270 | 0.340 |
Why?
|
Hematology | 1 | 2011 | 101 | 0.340 |
Why?
|
Wolman Disease | 1 | 2009 | 7 | 0.340 |
Why?
|
Sterol Esterase | 1 | 2009 | 17 | 0.340 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 1260 | 0.330 |
Why?
|
Maternal-Fetal Exchange | 1 | 2009 | 89 | 0.330 |
Why?
|
Isoantibodies | 1 | 2009 | 122 | 0.330 |
Why?
|
Cellular Senescence | 1 | 2010 | 386 | 0.310 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 2342 | 0.300 |
Why?
|
Proportional Hazards Models | 5 | 2023 | 5091 | 0.300 |
Why?
|
Female | 30 | 2024 | 146823 | 0.290 |
Why?
|
Antineoplastic Agents | 4 | 2022 | 14505 | 0.290 |
Why?
|
Prognosis | 9 | 2024 | 22192 | 0.290 |
Why?
|
Male | 27 | 2024 | 127192 | 0.280 |
Why?
|
Myelodysplastic Syndromes | 1 | 2020 | 3066 | 0.280 |
Why?
|
Young Adult | 11 | 2022 | 22111 | 0.280 |
Why?
|
Case-Control Studies | 4 | 2021 | 6025 | 0.280 |
Why?
|
Incidence | 4 | 2020 | 5874 | 0.270 |
Why?
|
HLA Antigens | 1 | 2009 | 551 | 0.270 |
Why?
|
Electronics | 2 | 2023 | 56 | 0.260 |
Why?
|
Methotrexate | 3 | 2024 | 1024 | 0.260 |
Why?
|
Survivorship | 2 | 2024 | 116 | 0.260 |
Why?
|
Intellectual Disability | 1 | 2013 | 1039 | 0.260 |
Why?
|
Longitudinal Studies | 2 | 2021 | 2049 | 0.250 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 1129 | 0.250 |
Why?
|
Lymphocyte Count | 3 | 2022 | 489 | 0.240 |
Why?
|
Societies, Medical | 1 | 2011 | 1393 | 0.240 |
Why?
|
Infant | 10 | 2022 | 13767 | 0.220 |
Why?
|
Biomarkers, Tumor | 2 | 2019 | 10581 | 0.210 |
Why?
|
Body Fluids | 1 | 2023 | 129 | 0.210 |
Why?
|
Asparaginase | 1 | 2022 | 186 | 0.200 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2022 | 101 | 0.200 |
Why?
|
Central Venous Catheters | 1 | 2022 | 100 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2024 | 1329 | 0.190 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 171 | 0.180 |
Why?
|
Atrial Function, Left | 1 | 2020 | 29 | 0.180 |
Why?
|
Retrospective Studies | 12 | 2024 | 39453 | 0.180 |
Why?
|
Aftercare | 2 | 2022 | 257 | 0.180 |
Why?
|
Follow-Up Studies | 5 | 2024 | 15183 | 0.180 |
Why?
|
Thyroid Diseases | 1 | 2020 | 87 | 0.180 |
Why?
|
Hypersensitivity | 1 | 2022 | 224 | 0.170 |
Why?
|
Pancreatitis | 1 | 2022 | 279 | 0.170 |
Why?
|
Echocardiography, Doppler | 1 | 2020 | 183 | 0.170 |
Why?
|
Poverty | 1 | 2023 | 498 | 0.170 |
Why?
|
Papillomavirus Vaccines | 1 | 2022 | 205 | 0.170 |
Why?
|
Adult | 13 | 2024 | 80478 | 0.170 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 2075 | 0.170 |
Why?
|
Catheterization, Central Venous | 1 | 2022 | 364 | 0.160 |
Why?
|
Catheter-Related Infections | 1 | 2022 | 272 | 0.160 |
Why?
|
Introns | 1 | 2020 | 433 | 0.160 |
Why?
|
Anthracyclines | 1 | 2020 | 332 | 0.160 |
Why?
|
Aging, Premature | 1 | 2018 | 40 | 0.160 |
Why?
|
Bacterial Infections | 1 | 2022 | 484 | 0.160 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 657 | 0.150 |
Why?
|
Heart Atria | 1 | 2020 | 367 | 0.150 |
Why?
|
Fatal Outcome | 2 | 2011 | 834 | 0.150 |
Why?
|
Cohort Studies | 3 | 2021 | 9448 | 0.150 |
Why?
|
Stroke Volume | 1 | 2020 | 605 | 0.150 |
Why?
|
Cerebellar Neoplasms | 1 | 2022 | 469 | 0.150 |
Why?
|
Renal Insufficiency | 1 | 2020 | 329 | 0.140 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 367 | 0.140 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 547 | 0.140 |
Why?
|
Longevity | 1 | 2018 | 154 | 0.140 |
Why?
|
Gene Frequency | 1 | 2020 | 1124 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2020 | 358 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 731 | 0.140 |
Why?
|
Medulloblastoma | 1 | 2022 | 571 | 0.140 |
Why?
|
Infant, Newborn | 5 | 2022 | 8540 | 0.140 |
Why?
|
Leukocytes | 1 | 2018 | 419 | 0.140 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 448 | 0.140 |
Why?
|
Sepsis | 1 | 2022 | 668 | 0.140 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 615 | 0.130 |
Why?
|
Radiation Pneumonitis | 1 | 2018 | 308 | 0.130 |
Why?
|
Parent-Child Relations | 1 | 2017 | 263 | 0.130 |
Why?
|
Patient Care Planning | 1 | 2018 | 308 | 0.130 |
Why?
|
Genetic Association Studies | 1 | 2020 | 1062 | 0.130 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 793 | 0.130 |
Why?
|
Chronic Disease | 1 | 2020 | 1860 | 0.120 |
Why?
|
Texas | 3 | 2023 | 6439 | 0.120 |
Why?
|
Lung Diseases | 1 | 2020 | 742 | 0.120 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 818 | 0.120 |
Why?
|
Induction Chemotherapy | 1 | 2018 | 672 | 0.120 |
Why?
|
T-Lymphocytes | 2 | 2021 | 3948 | 0.120 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 106 | 0.120 |
Why?
|
Echocardiography | 1 | 2020 | 1261 | 0.120 |
Why?
|
Pilot Projects | 1 | 2021 | 2863 | 0.120 |
Why?
|
Heart Diseases | 1 | 2020 | 754 | 0.120 |
Why?
|
Alleles | 1 | 2020 | 2391 | 0.110 |
Why?
|
Papillomavirus Infections | 1 | 2022 | 1009 | 0.110 |
Why?
|
Neoplasm Grading | 1 | 2018 | 1803 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 1117 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 1424 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2018 | 653 | 0.110 |
Why?
|
Surveys and Questionnaires | 2 | 2024 | 5917 | 0.110 |
Why?
|
Remission Induction | 2 | 2016 | 3621 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2020 | 1449 | 0.100 |
Why?
|
Pedigree | 2 | 2014 | 1879 | 0.100 |
Why?
|
Inpatients | 1 | 2017 | 699 | 0.100 |
Why?
|
Sex Distribution | 1 | 2013 | 506 | 0.100 |
Why?
|
Epilepsy | 1 | 2020 | 933 | 0.100 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 281 | 0.100 |
Why?
|
Age Distribution | 1 | 2013 | 713 | 0.100 |
Why?
|
Acute Disease | 1 | 2016 | 2472 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1969 | 0.100 |
Why?
|
Quality of Life | 2 | 2024 | 4716 | 0.090 |
Why?
|
Delivery of Health Care | 1 | 2018 | 883 | 0.090 |
Why?
|
Homozygote | 1 | 2013 | 739 | 0.090 |
Why?
|
Bone Marrow | 1 | 2018 | 2387 | 0.090 |
Why?
|
Biopsy | 1 | 2018 | 3494 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2019 | 10085 | 0.090 |
Why?
|
Anxiety | 1 | 2017 | 1245 | 0.090 |
Why?
|
Philadelphia Chromosome | 1 | 2014 | 827 | 0.090 |
Why?
|
Algorithms | 1 | 2021 | 3962 | 0.090 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 495 | 0.090 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 41 | 0.080 |
Why?
|
Germ-Line Mutation | 1 | 2014 | 1051 | 0.080 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2014 | 1127 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1269 | 0.080 |
Why?
|
DNA Methylation | 1 | 2018 | 2719 | 0.080 |
Why?
|
Middle Aged | 5 | 2021 | 89237 | 0.080 |
Why?
|
Risk Assessment | 1 | 2021 | 7106 | 0.080 |
Why?
|
Liver Failure | 1 | 2009 | 142 | 0.080 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 2492 | 0.070 |
Why?
|
Mutation | 2 | 2020 | 15578 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6259 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 4894 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2013 | 4360 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 5005 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2010 | 16015 | 0.060 |
Why?
|
Aging | 1 | 2013 | 1569 | 0.060 |
Why?
|
Neuroblastoma | 1 | 2010 | 695 | 0.060 |
Why?
|
Selection Bias | 1 | 2024 | 48 | 0.060 |
Why?
|
NF-kappa B | 1 | 2010 | 1576 | 0.060 |
Why?
|
Glioma | 1 | 2014 | 1981 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2082 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 3837 | 0.050 |
Why?
|
Personal Satisfaction | 1 | 2023 | 132 | 0.050 |
Why?
|
Hypokalemia | 1 | 2022 | 57 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 9303 | 0.050 |
Why?
|
Risk | 2 | 2018 | 1959 | 0.050 |
Why?
|
Demography | 1 | 2022 | 453 | 0.050 |
Why?
|
Drug Therapy | 1 | 2021 | 204 | 0.050 |
Why?
|
Creatinine | 1 | 2023 | 552 | 0.050 |
Why?
|
Systole | 1 | 2020 | 206 | 0.040 |
Why?
|
DNA Helicases | 1 | 2022 | 449 | 0.040 |
Why?
|
Transplantation Conditioning | 1 | 2009 | 2302 | 0.040 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 1217 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2021 | 525 | 0.040 |
Why?
|
Papillomaviridae | 1 | 2022 | 626 | 0.040 |
Why?
|
Phenotype | 1 | 2010 | 6326 | 0.040 |
Why?
|
Cardiotoxicity | 1 | 2020 | 161 | 0.040 |
Why?
|
Biomarkers | 1 | 2010 | 5154 | 0.040 |
Why?
|
Overweight | 1 | 2022 | 493 | 0.040 |
Why?
|
Hospitals, Pediatric | 1 | 2023 | 787 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2022 | 637 | 0.040 |
Why?
|
Qualitative Research | 1 | 2021 | 627 | 0.040 |
Why?
|
Recurrence | 2 | 2020 | 4875 | 0.040 |
Why?
|
Observer Variation | 1 | 2020 | 710 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 5475 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2014 | 4982 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2023 | 650 | 0.040 |
Why?
|
Family | 1 | 2021 | 743 | 0.040 |
Why?
|
Program Evaluation | 1 | 2020 | 623 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2023 | 1394 | 0.040 |
Why?
|
Bleomycin | 1 | 2018 | 467 | 0.030 |
Why?
|
Pregnancy | 1 | 2009 | 7819 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 314 | 0.030 |
Why?
|
Parents | 1 | 2023 | 1046 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2014 | 3069 | 0.030 |
Why?
|
Apoptosis | 1 | 2010 | 7739 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1019 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 1429 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 3059 | 0.030 |
Why?
|
Registries | 1 | 2023 | 2281 | 0.030 |
Why?
|
Kidney | 1 | 2023 | 2199 | 0.030 |
Why?
|
Patient Care Team | 1 | 2020 | 833 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 2014 | 106 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2022 | 970 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 2728 | 0.030 |
Why?
|
Hospitalization | 1 | 2023 | 2213 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2018 | 2269 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1891 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2020 | 34218 | 0.030 |
Why?
|
Pediatrics | 1 | 2021 | 1187 | 0.030 |
Why?
|
Prevalence | 1 | 2019 | 3391 | 0.020 |
Why?
|
Body Mass Index | 1 | 2018 | 2280 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 4543 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2020 | 6172 | 0.020 |
Why?
|
Gangliosides | 1 | 2010 | 110 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 3974 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2010 | 468 | 0.020 |
Why?
|
Exome | 1 | 2014 | 1267 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 2473 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2018 | 4452 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3266 | 0.020 |
Why?
|
Lung | 1 | 2018 | 3221 | 0.020 |
Why?
|
Time Factors | 1 | 2020 | 13246 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2010 | 716 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 1697 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2010 | 1133 | 0.020 |
Why?
|
Tumor Burden | 1 | 2010 | 2018 | 0.010 |
Why?
|
Blotting, Western | 1 | 2010 | 3576 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3628 | 0.010 |
Why?
|
Aged | 2 | 2023 | 72701 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2010 | 5509 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 13287 | 0.010 |
Why?
|
United States | 1 | 2020 | 16290 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 7745 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 6174 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 7296 | 0.010 |
Why?
|
Signal Transduction | 1 | 2010 | 12095 | 0.010 |
Why?
|